Litcius/Paper detail

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial

Kenneth Kintu, Thokozile R. Malaba, Jesca Nakibuka, Christiana Papamichael, Angela Colbers, Kelly Byrne, Kay Seden, Eva Maria Hodel, Tao Chen, Adelline Twimukye, Josaphat Byamugisha, Helen Reynolds, Victoria Watson, David M. Burger, Duolao Wang, Catriona Waitt, Miriam Taegtmeyer, Catherine Orrell, Mohammed Lamorde, Landon Myer, Saye Khoo

2020The Lancet HIV125 citationsDOIOpen Access PDF

Topics & Concepts

DolutegravirEfavirenzMedicinePregnancyAdverse effectObstetricsGestationViral loadRandomized controlled trialPediatricsPostpartum periodAntiretroviral therapyHuman immunodeficiency virus (HIV)Internal medicineVirologyGeneticsBiologyHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial | Litcius